495 related articles for article (PubMed ID: 24462190)
1. Managing the manager: gut microbes, stem cells and metabolism.
Serino M; Blasco-Baque V; Nicolas S; Burcelin R
Diabetes Metab; 2014 Jun; 40(3):186-90. PubMed ID: 24462190
[TBL] [Abstract][Full Text] [Related]
2. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
[TBL] [Abstract][Full Text] [Related]
3. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice.
Cani PD; Bibiloni R; Knauf C; Waget A; Neyrinck AM; Delzenne NM; Burcelin R
Diabetes; 2008 Jun; 57(6):1470-81. PubMed ID: 18305141
[TBL] [Abstract][Full Text] [Related]
4. Microbes on-air: gut and tissue microbiota as targets in type 2 diabetes.
Serino M; Blasco-Baque V; Burcelin R
J Clin Gastroenterol; 2012 Oct; 46 Suppl():S27-8. PubMed ID: 22955352
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the gut microbiota in leptin deficient obese mice - Correlation to inflammatory and diabetic parameters.
Ellekilde M; Krych L; Hansen CH; Hufeldt MR; Dahl K; Hansen LH; Sørensen SJ; Vogensen FK; Nielsen DS; Hansen AK
Res Vet Sci; 2014 Apr; 96(2):241-50. PubMed ID: 24556473
[TBL] [Abstract][Full Text] [Related]
6. Metabolic endotoxemia initiates obesity and insulin resistance.
Cani PD; Amar J; Iglesias MA; Poggi M; Knauf C; Bastelica D; Neyrinck AM; Fava F; Tuohy KM; Chabo C; Waget A; Delmée E; Cousin B; Sulpice T; Chamontin B; Ferrières J; Tanti JF; Gibson GR; Casteilla L; Delzenne NM; Alessi MC; Burcelin R
Diabetes; 2007 Jul; 56(7):1761-72. PubMed ID: 17456850
[TBL] [Abstract][Full Text] [Related]
7. The probiotic Lactobacillus coryniformis CECT5711 reduces the vascular pro-oxidant and pro-inflammatory status in obese mice.
Toral M; Gómez-Guzmán M; Jiménez R; Romero M; Sánchez M; Utrilla MP; Garrido-Mesa N; Rodríguez-Cabezas ME; Olivares M; Gálvez J; Duarte J
Clin Sci (Lond); 2014 Jul; 127(1):33-45. PubMed ID: 24410749
[TBL] [Abstract][Full Text] [Related]
8. The gut microbiota, obesity and insulin resistance.
Shen J; Obin MS; Zhao L
Mol Aspects Med; 2013 Feb; 34(1):39-58. PubMed ID: 23159341
[TBL] [Abstract][Full Text] [Related]
9. [Physiological patterns of intestinal microbiota. The role of dysbacteriosis in obesity, insulin resistance, diabetes and metabolic syndrome].
Halmos T; Suba I
Orv Hetil; 2016 Jan; 157(1):13-22. PubMed ID: 26708682
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus.
Allin KH; Nielsen T; Pedersen O
Eur J Endocrinol; 2015 Apr; 172(4):R167-77. PubMed ID: 25416725
[TBL] [Abstract][Full Text] [Related]
11. Interactions between gut microbiota and host metabolism predisposing to obesity and diabetes.
Musso G; Gambino R; Cassader M
Annu Rev Med; 2011; 62():361-80. PubMed ID: 21226616
[TBL] [Abstract][Full Text] [Related]
12. Targeting gut microbiota as a possible therapy for diabetes.
He C; Shan Y; Song W
Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
[TBL] [Abstract][Full Text] [Related]
13. Do nutrient-gut-microbiota interactions play a role in human obesity, insulin resistance and type 2 diabetes?
Diamant M; Blaak EE; de Vos WM
Obes Rev; 2011 Apr; 12(4):272-81. PubMed ID: 20804522
[TBL] [Abstract][Full Text] [Related]
14. Role of microbiota-derived lipopolysaccharide in adipose tissue inflammation, adipocyte size and pyroptosis during obesity.
Hersoug LG; Møller P; Loft S
Nutr Res Rev; 2018 Dec; 31(2):153-163. PubMed ID: 29362018
[TBL] [Abstract][Full Text] [Related]
15. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
16. Insulin Sensitivity-Enhancing Activity of Phlorizin Is Associated with Lipopolysaccharide Decrease and Gut Microbiota Changes in Obese and Type 2 Diabetes (db/db) Mice.
Mei X; Zhang X; Wang Z; Gao Z; Liu G; Hu H; Zou L; Li X
J Agric Food Chem; 2016 Oct; 64(40):7502-7511. PubMed ID: 27635781
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury.
Frazier TH; DiBaise JK; McClain CJ
JPEN J Parenter Enteral Nutr; 2011 Sep; 35(5 Suppl):14S-20S. PubMed ID: 21807932
[TBL] [Abstract][Full Text] [Related]
18. Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding.
Cani PD; Delzenne NM; Amar J; Burcelin R
Pathol Biol (Paris); 2008 Jul; 56(5):305-9. PubMed ID: 18178333
[TBL] [Abstract][Full Text] [Related]
19. Gut microbiota interactions with obesity, insulin resistance and type 2 diabetes: did gut microbiote co-evolve with insulin resistance?
Esteve E; Ricart W; Fernández-Real JM
Curr Opin Clin Nutr Metab Care; 2011 Sep; 14(5):483-90. PubMed ID: 21681087
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between the gut microbiota and the endocannabinoid system: impact on the gut barrier function and the adipose tissue.
Cani PD
Clin Microbiol Infect; 2012 Jul; 18 Suppl 4():50-3. PubMed ID: 22647050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
